How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
Conventional and Alternative Pain Treatment Market
- By Treatment Type: Pharmacological Treatments, Physical Therapy, Acupuncture, Chiropractic Care, Cognitive Behavioral Therapy, Transcutaneous Electrical Nerve Stimulation (TENS)
- By Pain Type: Chronic Pain, Acute Pain, Neuropathic Pain, Musculoskeletal Pain, Cancer Pain
- By End User: Hospitals, Pain Clinics, Home Care Settings, Rehabilitation Centers, Specialty Clinics
- By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Direct Sales, Specialty Clinics
- By Therapeutic Approach: Opioid Analgesics, Non-Opioid Analgesics, Complementary and Alternative Medicine (CAM), Interventional Pain Management, Mind-Body Techniques
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Pharmacological Treatments leads By Treatment Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 16 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
12 chapters · 310 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.66 →
- 11 Competitive Landscape 5 sections p.187 →
- 12 Company Profiles 16 players: SWOT & benchmarking p.195 →
Full report · locked preview
Everything inside the Conventional and Alternative Pain Treatment Market report
A complete, evidence-based study - 12 chapters and 130 sections covering market size, segmentation across 5 axes, regional analysis and 16 company profiles, forecast to 2033.
Segmentation covered
Companies profiled
★★★★★ Excellent
16 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Johnson & Johnson
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Pfizer Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →AbbVie Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Novartis AG
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Teva Pharmaceutical Industries Ltd.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Mylan N.V. (now part of Viatris)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Bayer AG
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.191 →Eli Lilly and Company
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Sanofi S.A.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →GlaxoSmithKline plc
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Mallinckrodt Pharmaceuticals
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Endo International plc
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →Grünenthal GmbH
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →Helsinn Group
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Zogenix
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Inc.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.245 →Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Pharmacological Treatments37.4
- Physical Therapy11.4
- Acupuncture15.4
- Chiropractic Care11.2
- Cognitive Behavioral Therapy15.1
- Transcutaneous Electrical Nerve Stimulation (TENS)9.6
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Johnson & Johnson12.0
- Pfizer Inc.19.3
- AbbVie Inc.9.8
- Novartis AG13.2
- Teva Pharmaceutical Industries Ltd.11.7
- Mylan N.V. (now part of Viatris)6.1
- Others27.9
Segment contribution to growth (%)
Fig. 18 · p.39 →Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America31.7
- Europe26.0
- Asia Pacific20.1
- Latin America12.5
- Middle East and Africa9.7
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Johnson & Johnson | 92 | 95 | 76 | 81 | 82 | 85 | 85 |
| Pfizer Inc. | 93 | 75 | 83 | 68 | 90 | 90 | 83 |
| AbbVie Inc. | 69 | 88 | 66 | 78 | 86 | 67 | 76 |
| Novartis AG | 65 | 81 | 74 | 60 | 63 | 78 | 70 |
| Teva Pharmaceutical Industries Ltd. | 52 | 54 | 65 | 54 | 68 | 67 | 60 |
| Mylan N.V. (now part of Viatris) | 66 | 71 | 54 | 64 | 59 | 64 | 63 |
| Bayer AG | 58 | 43 | 55 | 50 | 55 | 51 | 52 |
| Eli Lilly and Company | 58 | 56 | 60 | 47 | 46 | 45 | 52 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Johnson & Johnson
- Pfizer Inc.
- AbbVie Inc.
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Johnson & Johnson | ◐ | ✓ | ✓ | ◐ | ◐ | ◐ |
| Pfizer Inc. | ◐ | ✓ | ✓ | ✓ | ✓ | ◐ |
| AbbVie Inc. | ◐ | ✓ | ◐ | ◐ | ✓ | ✓ |
| Novartis AG | ◐ | ✓ | − | − | ◐ | ◐ |
| Teva Pharmaceutical Industries Ltd. | − | ◐ | ◐ | ◐ | ✓ | − |
| Mylan N.V. (now part of Viatris) | ✓ | − | − | − | ◐ | ◐ |
| Bayer AG | − | − | ◐ | ◐ | − | − |
| Eli Lilly and Company | − | − | − | − | − | ◐ |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
Challenger2
Strong scale, closing on the leaders.
Contender2
Focused players with pockets of strength.
Niche2
Specialists in a single segment or region.
Go-to-market strategy
Land Treatment Type in North America, then scale across Conventional and Alternative Pain Treatment Market — a $132M beachhead inside a $2.28B market.
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Pharmacological Treatments
Best fit — highest urgency & budget in Treatment Type.
Physical Therapy
Strong fit — clear ROI and a fast path to value.
Acupuncture
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Treatment Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Pain Type & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + End User
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Positioning & messaging
§GTM 2 · p.194 →For Treatment Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Conventional and Alternative Pain Treatment Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Investment thesis
Conventional and Alternative Pain Treatment Market is a resilient opportunity — $2.76B by 2033, compounding at 5.8%.
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →5.8% CAGR
Demand compounds through 2033, outpacing GDP across Treatment Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Treatment Type moving from early to mainstream — durable secular demand.
Consolidation upside
16+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →Return scenarios (2033 market value)
Fig. 6 · p.22 →Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Pain Type optionality
- Customer concentrationBroaden installed base beyond top accounts
Board pack · executive summary
Conventional and Alternative Pain Treatment Market — a $1.28B market by 2033. Plan: grow share from 8.4% to 17.1%.
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 8.4% | 17.1% | On track |
| Revenue | $102M | $218M | Behind |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | On track |
| Segment coverage | 3 of 5 axes | 5 of 5 axes | Behind |
| Gross margin | 36.1% | 43.4% | On track |
| Customer retention | 86.3% | 93.3% | On track |
Where to play (strategic priorities)
§1.2 · p.8 →Lead segment
Win in Treatment Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
Adjacency
Build Pain Type capability
A defensible second engine — invest in Pain Type to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Treatment Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Pain Type
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $30M capacity & capability investment
- Greenlight bolt-on M&A in Pain Type
- Authorise North America expansion plan
- Fund R&D program for Treatment Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownBehind
- Competitive share lossOn track
- Input-cost & supply riskOn track
- Regulatory / policy changeAhead
- Execution & talentOn track
Sales deck · value proposition
Win the Conventional and Alternative Pain Treatment Market conversation — a $6.80B market you can size, segment and defend in minutes.
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Treatment Type
Goal Grow share in Treatment Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →The business case (ROI)
Fig. 2 · p.9 →Why buyers trust it (proof points)
§1.3 · p.12 →Coverage includes
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Conventional and Alternative Pain Treatment Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
Your report is ready to access
Conventional and Alternative Pain Treatment Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →Convenient Care Clinics Market
Market size, share, segmentation and regional forecast.
$2.0B market · 2025 base year
View reportConvection Laboratory Incubator Market
Market size, share, segmentation and regional forecast.
$4.5B market · 2025 base year
View reportConvalescent Plasma Therapy Market
Market size, share, segmentation and regional forecast.
$4.1B market · 2025 base year
View reportUrinary Products Market
Market size, share, segmentation and regional forecast.
$3.9B market · 2025 base year
View reportControl Syringe Market
Market size, share, segmentation and regional forecast.
$1.2B market · 2025 base year
View reportControl Software for Pharmaceutical Water System Market
Market size, share, segmentation and regional forecast.
$4.7B market · 2025 base year
View reportControlled Substances Market
Market size, share, segmentation and regional forecast.
$1.3B market · 2025 base year
View reportControlled Substance Disposal Service Market
Market size, share, segmentation and regional forecast.
$3.4B market · 2025 base year
View reportControlled Room Temperature (CRT) Cabinets Market
Market size, share, segmentation and regional forecast.
$3.7B market · 2025 base year
View reportWalking Canes Market
Walking Canes Market is valued at USD 1.85 Billion in 2025 and is expected to reach USD 2.46 Bi…
$1.9B market · 2025 base year
View reportControlled-Release Drug Delivery Technology Market
Market size, share, segmentation and regional forecast.
$1.7B market · 2025 base year
View reportDisposable Clothing Market
Market size, share, segmentation and regional forecast.
$4.4B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy